Drawing for POWDERHALE

USPTO serial 98286234

POWDERHALE

Reviewed by CopyMark Law Group

Reg. 7543028Status 700Registered
Filing date
Status date
Registration date
Oct 22, 2024
Examiner
PERRY, KIMBERLY B
Law office
FILE REPOSITORY (FRANCONIA)

What this means

Status 700 means the trademark is registered and active on the Principal Register. You have nationwide rights for the listed goods and services and may use ®. Section 8 maintenance is due between years five and six. Calendar Section 8 between years five and six, and consider trademark monitoring.

Status 700: Status 700 means the trademark is registered and active on the Principal Register. You have nationwide rights for the listed goods and services and may use ®. Section 8 maintenance is due between years five and six.

Need help with POWDERHALE?

If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.

Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.

Owner

Attorney of record

The USPTO lists this attorney as the applicant's representative for correspondence on this application.

Molly B. Markley

MOLLY B. MARKLEY YOUNG, BASILE, HANLON & MACFARLANE P.C.3001 WEST BIG BEAVER ROADSUITE 624TROY, MI 48084

Goods and services

ClassDescriptionStatusFirst use
005Pharmaceutical and veterinary preparations for the treatment of diseases or conditions of the respiratory system; pharmaceutical and veterinary preparations for the treatment of diseases or conditions of the respiratory system, diseases or conditions of the cardiovascular system, diabetes, cancer, arthritis, diseases or conditions of the gastro-intestinal system, diseases or conditions of the central nervous system, diseases or conditions of the endocrine system, diseases or conditions of the genito-urinary system, infections, skin disorders and gynecological conditions; pharmaceutical and veterinary preparations for the alleviation or prevention of pain or inflammation; inhalers filled with powders for the treatment of diseases or conditions of the respiratory system, diseases or conditions of the cardiovascular system, diabetes, cancer, arthritis, diseases or conditions of the gastro-intestinal system, diseases or conditions of the central nervous system, diseases or conditions of the endocrine system, diseases or conditions of the genito-urinary system, infections, skin disorders and gynecological conditions; pharmaceutical preparations, namely, powders for asthma inhalers; pharmaceutical preparations, namely, powders for transdermal injection for the alleviation or prevention of pain, for the treatment of diseases or conditions of the respiratory system, diseases or conditions of the cardiovascular system, diabetes, cancer, arthritis, diseases or conditions of the gastro-intestinal system, diseases or conditions of the central nervous system, diseases or conditions of the endocrine system, diseases or conditions of the genito-urinary system, infections, skin disorders and gynecological conditions; pharmaceutical and veterinary preparations for oral ingestion for the treatment of diseases or conditions of the respiratory system, diseases or conditions of the cardiovascular system, diabetes, cancer, arthritis, diseases or conditions of the gastro-intestinal system, diseases or conditions of the central nervous system, diseases or conditions of the endocrine system, diseases or conditions of the genito-urinary system, infections, skin disorders and gynecological conditions; pharmaceutical and veterinary preparations for topical administration for the treatment of diseases or conditions of the respiratory system, diseases or conditions of the cardiovascular system, diabetes, cancer, arthritis, diseases or conditions of the gastro-intestinal system, diseases or conditions of the central nervous system, diseases or conditions of the endocrine system, diseases or conditions of the genito-urinary system, infections, skin disorders and gynecological conditions; pharmaceutical and veterinary preparations for erectile dysfunction; pharmaceutical and veterinary preparations for chronic obstructive pulmonary disease; pharmaceutical and veterinary preparations for premature ejaculation; pharmaceutical and veterinary preparations for cystic fibrosis; pharmaceutical and veterinary preparations for female sexual dysfunction; medicaments for migraine; pharmaceutical and veterinary preparations for asthmaACTIVE—
010Inhalers for medical purposes, sold empty; metered dose inhalers for medical purposes, sold empty; active dry powder inhalers for medical purposes, sold empty; passive dry powder inhalers for medical purposes, sold empty; nebulisers for respiration therapy; respirators for artificial respiration and parts and fittings for all the aforesaid goodsACTIVE—

Related trademarks

CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.

Prosecution history

DateCodeEventWhat it means
Oct 22, 2024NRCCNOTICE OF REGISTRATION CONFIRMATION EMAILED—
Oct 22, 2024R.PRREGISTERED-PRINCIPAL REGISTERYour trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive.
Aug 6, 2024NPUBOFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED—
Aug 6, 2024PUBOPUBLISHED FOR OPPOSITIONYour mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance.
Jul 17, 2024NONPNOTIFICATION OF NOTICE OF PUBLICATION E-MAILED—
Jun 13, 2024ERRRON HOLD - ELECTRONIC RECORD REVIEW REQUIRED—
Jun 11, 2024CNSAAPPROVED FOR PUB - PRINCIPAL REGISTER—
May 29, 2024DOCKASSIGNED TO EXAMINER—
Jan 18, 2024NWOSNEW APPLICATION OFFICE SUPPLIED DATA ENTERED—
Nov 30, 2023NWAPNEW APPLICATION ENTERED—

Frequently asked questions

Related guidance